By Dr Nicola Davies
Translational science is intended to bring predictivity and efficacy to the development and dissemination of interventions that improve human health, turning science discoveries into therapeutic applications.1
To meet these objectives, the Office of Translational Sciences (OTS) is comprised of a multidisciplinary team responsible for supporting the mission of the US Food and Drug Administration (FDA) through a multitude of strategic initiatives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze